Cognitive enhancers don't improve cognition, function in people with mild cognitive impairment

September 16, 2013

Cognitive enhancers—drugs taken to enhance concentration, memory, alertness and moods—do not improve cognition or function in people with mild cognitive impairment in the long term, according to a new study by researchers at St. Michael's Hospital.

In fact, patients on these medications experienced significantly more nausea, diarrhea, vomiting and headaches, according to the study published today in the Canadian Medical Association Journal.

"Our findings do not support the use of cognitive enhancers for mild cognitive impairment," wrote Dr. Andrea Tricco and Dr. Sharon Straus, who are both scientists in the hospital's Li Ka Shing Knowledge Institute. Dr. Straus is also a geriatrician at the hospital.

Mild cognitive impairment is a condition characterized by without significant limitations in everyday activity. Between 3 and 42 per cent of people are diagnosed with the condition each year, about 4.6 million people worldwide. Each year about 3 to 17 per cent of people with mild cognitive impairment will develop dementia, such as Alzheimer's disease. Given the , it's estimated the number of Canadians with dementia will double to more than 1 million in the next 25 years.

It has been hypothesized that cognitive enhancers may delay the onset of dementia. Families and patients are increasingly requesting these drugs even though their efficacy for patients with mild cognitive impairment has not been established. In Canada, cognitive enhancers can be obtained only with special authorization.

Drs. Tricco and Straus conducted a review of existing evidence to understand the efficacy and safety of cognitive enhancers. They looked at eight that compared one of four cognitive enhancers (donepezil, , galantamine or ) to a placebo among patients diagnosed with mild cognitive impairment.

While they found short-term benefits to using these drugs on one cognition scale, there were no long-term effects after about a year and a half. No other benefits were observed on the second cognition scale or on function, behaviour, and mortality. As well, patients on these medications experienced significantly more nausea, diarrhea, vomiting and headaches. One study also found a higher risk of a heart condition known as bradycardia (slow heartbeat) among patients who received .

"Our results do not support the use of cognitive enhancers for patients with mild cognitive impairment," the authors wrote. "These agents were not associated with any benefit and led to an increase in harms. Patients and their families should consider this information when requesting these medications. Similarly, health care decision-makers may not wish to approve the use of these medications for , because these drugs might not be effective and are likely associated with harm."

This study was funded by the Drug Safety and Effectiveness Network/Canadian Institutes of Health Research.

Another St. Michael's study published in the CMAJ in April found no evidence that drugs, herbal products or vitamin supplements help prevent cognitive decline in healthy older adults. That review, led by Dr. Raza Naqvi, a University of Toronto resident, found some evidence that mental exercises, such as computerized memory training programs, might help.

Explore further: No evidence drugs, vitamins, supplements help prevent cognitive decline in healthy older adults

More information:

Related Stories

Preventing cognitive decline in healthy seniors

April 15, 2013

Cognitive training exercises—or mental exercise—may help prevent cognitive decline in healthy older adults, while evidence for the benefits of pharmacologic substances and exercise is weak, outlines a review published ...

Cardiac disease linked to higher risk of mental impairment

January 28, 2013

Cardiac disease is associated with increased risk of mild cognitive impairment such as problems with language, thinking and judgment—particularly among women with heart disease, a Mayo Clinic study shows. Known as nonamnestic ...

Gene is marker only for mild cognitive impairment

February 12, 2013

Defying the widely held belief that a specific gene is the biggest risk factor for Alzheimer's disease, two Cornell developmental psychologists and their colleagues report that people with that gene are more likely to develop ...

Recommended for you

Neuro chip records brain cell activity

October 26, 2016

Brain functions are controlled by millions of brain cells. However, in order to understand how the brain controls functions, such as simple reflexes or learning and memory, we must be able to record the activity of large ...

After blindness, the adult brain can learn to see again

October 25, 2016

More than 40 million people worldwide are blind, and many of them reach this condition after many years of slow and progressive retinal degeneration. The development of sophisticated prostheses or new light-responsive elements, ...

The current state of psychobiotics

October 25, 2016

Now that we know that gut bacteria can speak to the brain—in ways that affect our mood, our appetite, and even our circadian rhythms—the next challenge for scientists is to control this communication. The science of psychobiotics, ...

Can a brain-computer interface convert your thoughts to text?

October 25, 2016

Ever wonder what it would be like if a device could decode your thoughts into actual speech or written words? While this might enhance the capabilities of already existing speech interfaces with devices, it could be a potential ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Sep 16, 2013
I rated low because the title insinuates that they reviewed all the cognitive enhancers available. They only evaluated 4 pharmaceutical enhancers. There are dozens at least, many of them are natural substances. And many of them work nicely.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.